Open AccessNanovectors for anti-cancer drug delivery in the treatment of advanced pancreatic adenocarcinoma
Author(s) -
Chung-Tzu Hsueh,
Julie H. Selim,
James Tsai,
Chung-Tsen Hsueh
Publication year - 2016
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v22.i31.7080
Subject(s) - pancreatic cancer , medicine , irinotecan , drug delivery , drug , paclitaxel , adenocarcinoma , pharmacology , cancer , pharmacokinetics , gemcitabine , polyethylene glycol , chemistry , colorectal cancer , organic chemistry
Liposome, albumin and polymer polyethylene glycol are nanovector formulations successfully developed for anti-cancer drug delivery. There are significant differences in pharmacokinetics, efficacy and toxicity between pre- and post-nanovector modification. The alteration in clinical pharmacology is instrumental for the future development of nanovector-based anticancer therapeutics. We have reviewed the results of clinical studies and translational research in nanovector-based anti-cancer therapeutics in advanced pancreatic adenocarcinoma, including nanoparticle albumin-bound paclitaxel and nanoliposomal irinotecan. Furthermore, we have appraised the ongoing studies incorporating novel agents with nanomedicines in the treatment of pancreatic adenocarcinoma.